1. Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
    Daniel Principe, 2022, Cancers CrossRef
  2. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
    Elisa D'Agostino et al, 2024, Cancer Treatment Reviews CrossRef
  3. Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities
    Fei-Fei Yang et al, 2024, RSC Medicinal Chemistry CrossRef
  4. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort
    Daniel R. Principe et al, 2020, Scientific Reports CrossRef
  5. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
    Ke Shen et al, 2022, Current Drug Targets CrossRef
  6. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer
    Sachin Sharma et al, 2023, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
  7. Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin
    Hua Yan et al, 2018, International Journal of Molecular Medicine CrossRef
  8. Dynamic monitoring and quantitative characterization of intracellular H2O2 content by using SERS based boric acid nanoprobe
    Wendai Cheng et al, 2020, Talanta CrossRef
  9. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives


    Lucia Musacchio et al, 2020, Cancer Management and Research CrossRef
  10. Molecular Targeted Therapy in Endometrial Cancer: Basis and Therapeutics
    Shruti Bhatia et al, 2020, Recent Advances in Endometrial Cancer CrossRef
  11. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
    Minakshi Mann et al, 2019, Oncotarget CrossRef